Stryker Corporation
SYK
$329.65
+0.09%
Stryker Corporation is a leading global medical technology company that designs, manufactures, and markets a comprehensive portfolio of medical equipment, instruments, consumable supplies, and implantable devices, operating within the Medical Devices industry. The company is a market leader in reconstructive orthopedic implants and holds the top position in operating room equipment, solidifying its identity as a dominant, diversified player in the healthcare sector. The current investor narrative centers on navigating a challenging market environment, as evidenced by recent price weakness and underperformance relative to the broader market, with attention likely focused on the company's ability to sustain its growth trajectory and margin profile amidst potential macroeconomic and competitive pressures in the medical device space.…
SYK
Stryker Corporation
$329.65
Related headlines
Investment Opinion: Should I buy SYK Today?
Rating & Thesis: Hold. Stryker is a high-quality company caught in a valuation and sentiment downdraft; investors should wait for either a more attractive entry point or clearer signs of fundamental re-acceleration before committing new capital. The limited analyst data shows a mix of Buy and Hold ratings, with the latest institutional action (UBS) being a Neutral reiteration, aligning with a cautious stance.
Supporting Evidence: The stock trades at a premium trailing PE of 41.38x, which is above its own recent history, but the forward PE of 20.50x suggests the market expects significant earnings growth. Revenue growth remains strong at 11.42% YoY, and profitability is solid with a 19.47% operating margin. However, the high PEG ratio of 5.16 and the severe -35.82% relative strength deficit versus the market indicate the current price does not offer a compelling margin of safety.
Risks & Conditions: The two biggest risks are 1) further multiple compression if growth slows, and 2) continued technical breakdown below the $319 support level. This Hold rating would upgrade to a Buy if the forward PE compressed further towards 18x on sustained growth, or if the stock established a firm base above its 200-day moving average signaling a trend reversal. It would downgrade to a Sell if revenue growth decelerated below 8% or net margins fell below 10%. The stock is currently fairly valued to slightly overvalued relative to its near-term growth prospects, but undervalued if its long-term earnings trajectory is achieved.
Sign up to view all
SYK 12-Month Price Forecast
Stryker presents a classic 'good company, questionable stock' scenario. Its fundamental business strength is undeniable, with robust growth, high margins, and fortress-like cash flow. However, the stock's technical damage, premium historical valuation, and the high bar set by forward earnings create a balanced risk/reward profile for the next 12 months. The base case of range-bound trading is most probable as the market digests these cross-currents. The stance would upgrade to Bullish on a confirmed breakout above $385 with volume, signaling the technical downtrend has broken. It would downgrade to Bearish on a sustained break below the $319 support level, which would indicate the fundamental story is cracking.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $428.54 and implied upside of +30.0% versus the current price.
Average Target
$428.54
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$264 - $429
Analyst target range
Analyst coverage for Stryker is limited in the provided dataset, with only 6 analysts contributing to estimates, which is lower than typical for a large-cap company and may indicate reduced institutional scrutiny or a focus on a narrower set of forecasts. The available data shows estimated EPS for the next period has a consensus of $23.10, with a range from $22.56 to $23.49, and estimated revenue averages $37.85 billion, but a consensus price target and recommendation distribution are not provided in the data. Without explicit target prices, the signal strength and implied upside cannot be calculated; the recent institutional ratings show a mix of Buy and Hold/Neutral actions, with the latest from UBS on March 17, 2026, being a reiteration of Neutral, suggesting a cautious but not bearish stance among those firms.
Bulls vs Bears: SYK Investment Factors
The evidence presents a stark conflict between strong fundamentals and weak market sentiment. The bull case is anchored in Stryker's robust 11.4% revenue growth, exceptional $4.3B free cash flow, and solid profitability metrics, which depict a high-quality, financially secure business. The bear case is driven by severe technical underperformance (-35.8% vs. S&P 500), an elevated trailing PE of 41.4x, and net margin compression, reflecting investor concerns over valuation and cost pressures. Currently, the bear side has stronger evidence in the near term, as price action and valuation multiples clearly signal market disapproval. The single most important tension is whether the company's strong fundamental growth and expected earnings rebound (implied by the 20.5x forward PE) can overcome the significant valuation overhang and technical damage that has been inflicted. The resolution of this tension—specifically, the next few quarters of earnings and margin performance—will determine the direction of the stock.
Bullish
- Strong Revenue Growth & Diversification: Q4 2025 revenue grew 11.42% YoY to $7.17B, with a diversified base between Orthopaedics ($4.96B) and MedSurg ($4.56B). Sequential quarterly growth from $5.87B to $7.17B demonstrates robust execution and demand across its portfolio.
- Exceptional Free Cash Flow Generation: The company generated $4.28B in trailing twelve-month free cash flow, providing immense financial flexibility. This strong cash flow supports dividends, share repurchases, and strategic M&A without straining the balance sheet.
- Solid Profitability & Healthy Margins: Gross margin remains high at 65.22% in Q4, and the operating margin is a solid 19.47%. A Return on Equity of 14.48% indicates efficient use of shareholder capital, underpinning the company's quality.
- Strong Balance Sheet & Low Financial Risk: With a current ratio of 1.89 and a manageable debt-to-equity ratio of 0.66, the balance sheet is robust. This financial strength provides a buffer against market downturns and funds future growth.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is down 0.92% over the past year, underperforming the S&P 500 by -35.82%. It trades near its 52-week low ($319.32), reflecting persistent bearish momentum and investor pessimism.
- Elevated Trailing Valuation Multiples: A trailing PE of 41.38x is above both sector averages and its own recent historical range (Q4 2025: 39.59x). This premium valuation limits near-term upside and increases vulnerability to multiple compression.
- Net Margin Compression & Cost Pressures: Q4 2025 net margin compressed to 11.84%, down from higher levels in prior quarters (e.g., Q3 2025: 14.18%). This raises concerns about the company's ability to manage costs and maintain profitability amidst growth.
- Limited Analyst Coverage & Cautious Sentiment: Only 6 analysts are tracked, suggesting reduced institutional scrutiny. Recent actions like UBS's 'Neutral' reiteration on March 17, 2026, point to a cautious, wait-and-see stance rather than strong conviction.
SYK Technical Analysis
The stock is in a pronounced downtrend, having declined 0.92% over the past year, which starkly contrasts with the S&P 500's 34.9% gain, resulting in a severe relative strength deficit of -35.82%. Currently trading at $343.32, the price sits at approximately 85% of its 52-week range ($319.32 to $404.87), indicating it is much closer to its yearly lows than highs, which may signal a value opportunity but also reflects significant bearish momentum and investor pessimism. The short-term momentum is negative and accelerating, with the stock down 5.62% over the last three months and 0.72% over the past month, diverging sharply from the positive market trends where the S&P 500 gained 2.67% and 7.36% over the same periods, respectively. This persistent underperformance suggests the stock is facing unique headwinds, and the recent 1-month decline within a longer-term downtrend could indicate a continuation of the bearish phase rather than a reversal. Key technical support is clearly defined at the 52-week low of $319.32, while resistance lies at the 52-week high of $404.87; a breakdown below support would likely trigger further selling, whereas a sustained move above resistance is needed to signal a trend reversal. With a beta of 0.926, the stock exhibits slightly less volatility than the overall market, but its significant drawdown of -19.19% highlights that it has been a source of idiosyncratic risk for investors recently.
Beta
0.93
0.93x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$319-$405
Price range past year
Annual Return
-7.7%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +0.3% | +8.5% |
| 3m | -7.2% | +2.8% |
| 6m | -13.7% | +4.6% |
| 1y | -7.7% | +32.3% |
| ytd | -5.3% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $7.171 billion representing an 11.42% year-over-year increase, and the business is diversified with Orthopaedics ($4.964 billion) and MedSurg ($4.562 billion) segments contributing nearly equally. The quarterly trend shows revenue growing sequentially from $5.866 billion in Q1 to $7.171 billion in Q4, indicating strong execution and demand, though investors will monitor if this pace can be sustained. The company is highly profitable, reporting Q4 net income of $849 million and a trailing twelve-month free cash flow of $4.283 billion, with gross margins holding at a healthy 65.22% for the quarter. Profitability metrics are solid, with a return on equity of 14.48% and an operating margin of 19.47%, though net margin compression to 11.84% in Q4 from higher levels in prior quarters warrants attention regarding cost management. The balance sheet is strong with a current ratio of 1.89 and a manageable debt-to-equity ratio of 0.66, while the substantial free cash flow generation of $4.283 billion provides ample internal funding for growth initiatives, dividends, and share repurchases, significantly reducing financial risk.
Quarterly Revenue
$7.2B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 41.38x and a forward PE of 20.50x, with the large gap indicating the market expects a significant earnings rebound in the coming year. Compared to sector averages, the trailing PE of 41.38x is elevated, but the forward multiple of 20.50x is more reasonable and suggests growth expectations are priced in; the Price-to-Sales ratio of 5.35x and EV/EBITDA of 22.99x provide additional context for its premium pricing within the medical devices space. Historically, the current trailing PE of 41.38x is above the stock's own recent historical range, as seen in Q4 2025 (39.59x) and Q3 2025 (41.14x), indicating the stock is trading at a premium to its recent valuation history, which may limit near-term upside unless earnings accelerate markedly.
PE
41.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~78x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Stryker's primary financial risk is valuation compression, given its elevated trailing PE of 41.38x and PEG ratio of 5.16, which are unsustainable if earnings growth decelerates. Operational risks include net margin pressure, as seen in the Q4 2025 compression to 11.84% from higher prior-quarter levels, potentially indicating rising costs or pricing pressures. While revenue is diversified across segments, a slowdown in elective orthopedic procedures—a key driver—could impact the high-margin Orthopaedics business, which contributed $4.96B in revenue.
Market & Competitive Risks: The stock faces significant market risk from its premium valuation (PS ratio of 5.35x, EV/EBITDA of 22.99x) relative to peers, making it vulnerable to sector-wide de-rating. Competitive risks are inherent in the medical device space, where innovation and pricing pressure are constant. The stock's beta of 0.926 suggests it is slightly less volatile than the market, but its -19.19% max drawdown and severe underperformance highlight unique, company-specific headwinds that may not be captured by beta alone.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current downtrend, triggered by a Q4 earnings miss that confirms margin deterioration and growth deceleration. This could lead to multiple compression towards the sector median and a re-test of the 52-week low. In this adverse scenario, the stock could realistically fall to its 52-week low of $319.32, representing a downside of approximately -7% from the current price of $343.32. A break below this key support could trigger further technical selling, potentially extending losses towards -15% to -20% if investor sentiment turns decisively negative.
FAQ
The key risks are, in order of severity: 1) Valuation Compression Risk: The high trailing PE of 41.4x makes the stock vulnerable to de-rating if growth slows. 2) Execution/Margin Risk: Net margin compressed to 11.84% in Q4 2025; further deterioration would hurt earnings. 3) Technical & Sentiment Risk: The stock is in a pronounced downtrend, down 5.6% over 3 months, and breaking below $319 support could trigger more selling. 4) Competitive/Market Risk: As a leader in orthopedic implants, it faces constant pricing and innovation pressure from peers like Zimmer Biomet and Johnson & Johnson.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $360 and $385 as it digests its valuation, implying modest upside from $343. The Bull Case (25% probability) targets $404 to $425 on strong earnings and multiple expansion. The Bear Case (15% probability) sees a re-test of support between $319 and $340 on growth deceleration. The Base Case is most likely, anchored by the expectation that Stryker will deliver steady, high-single-digit growth but struggle to command a higher valuation multiple in the near term.
SYK is fairly valued to slightly overvalued based on near-term metrics, but potentially undervalued if long-term growth materializes. The trailing PE of 41.38x is elevated compared to its own history and sector averages, indicating the market is paying a premium for past performance. However, the forward PE of 20.50x implies the market expects a sharp earnings rebound, pricing in future growth. The high PEG ratio of 5.16 signals the stock is expensive relative to its growth rate. Overall, the valuation is rich and implies the market expects flawless execution and sustained high growth to justify the current price.
SYK is a good stock for long-term investors seeking quality healthcare exposure, but it is not a compelling buy at the current moment. The stock has significantly underperformed the market (-35.8% over the past year) and trades at a premium trailing PE of 41.4x, suggesting limited near-term upside. However, its strong fundamentals—11.4% revenue growth, $4.3B in free cash flow, and a leadership position—make it a candidate for a watchlist. It becomes a good buy for patient investors if it dips closer to its 52-week low near $319, offering a better margin of safety.
SYK is unequivocally suitable for long-term investment, not short-term trading. Its business model—selling mission-critical medical devices—generates durable, recurring revenue and massive free cash flow ($4.3B TTM), which compounds over time. The stock's low beta of 0.93 indicates lower volatility than the market, supporting a buy-and-hold strategy. However, the current technical downtrend and valuation concerns make it a poor candidate for short-term trades. Investors should have a minimum holding period of 3-5 years to allow the company's fundamental strengths to overcome near-term market noise and realize the compounding potential of its cash flows.